Intracavernosal forskolin: Role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy Academic Article uri icon

Overview

MeSH Major

  • Zygomycosis

abstract

  • Forskolin is a United States Food and Drug Administration nonapproved vasoactive agent that acts in synergism with prostaglandin E1 to induce smooth muscle relaxation. In combination with other vasoactive agents, forskolin has demonstrated preliminary safety and efficacy in patients with vasculogenic impotence resistant to standard 3-agent pharmacotherapy.

publication date

  • November 1997

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S0022-5347(01)64118-1

Additional Document Info

start page

  • 1752

end page

  • 8; discussion 1758-9

volume

  • 158

number

  • 5